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Abstract
After having practicing and researching health economics for nearly 15 years now, it has become clear 
to me that the use of cost-effectiveness data in priority setting decisions is rather a rare than a common 
practice. The Eckard et al. article though, describes a wonderful exception to this rule and a very good 
example of how it can be used when the conditions are right. However, do we fully understand what these 
conditions are? In this commentary article I will address some of the institutional and cultural conditions 
that need to be fulfilled in order for cost-effectiveness data to actually be used in priority setting decisions.
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Introduction
Despite the large production of cost-effectiveness data 
worldwide, today it is fascinating that we know and understand 
so little about the actual use of health economic evaluations 
among the intended audience – the medical decision-makers. 
What happens after a health economic evaluation has been 
produced? Will it be used at all and, if so, how? Who uses 
economic evaluations and for what purposes? Are there 
differences in the use patterns between decision-makers at 
different healthcare levels? Are decision-makers able and 
willing to use them, and to what extent can the patterns be 
explained by contextual issues? 
Quite a few researchers have tried to address these questions 
in systematic literature reviews (1–10) over time. All reviews 
conclude that a health economic evaluation seldom is the 
decisive factor behind decision at regional or local level 
but sometimes on a national level. Whether the technology 
(predominately pharmaceuticals) should be reimbursed or 
recommended or not is decided by an independent committee 
and many times done in an explicit way (11). These reviews 
indicate that health economic evaluations primarily are 
used as grounds for decisions on reimbursement status or 
treatment guidance at a national level, and often in connection 
with authorities’ assessment of current and new technology 
in healthcare, like in the case provided by Eckard et al. (12). 
Yet, the great majority of priority setting decisions is taking 
place at the regional and local level under less formalized 
conditions. 
Having studied real world pharmaceutical priority setting 
on national, regional and local level in Sweden and 
internationally for several year, the conclusion reached in my 
doctorial thesis was that there are a few contextual conditions 
that need to be fulfilled in order for cost-effectiveness data 
to be incorporated into any part of priority setting. These 
conditions are as following; 1) lack of budget restrictions, 2) 
fit between data and decision-making rules legitimate to be 
used by decision-makers to reduce uncertainty, 3) demand 
for transparency, 4) internal and external institutions, and 5) 
existence of a prevailing template for how to incorporate (13). 
This framework will be used to analyse the results derived 
from Eckard et al. (12).
Budget restrictions
The occurrence of  budget restrictions is suggested to limit the 
use of cost-effectiveness data as few such evaluations inform 
decisions like how to optimize the budget on a healthcare 
department level. Due to its ability of enlighten healthcare 
managers with an estimated expenditure for an intervention 
(based on the expected unit cost and volume), budget impact 
analyses are speaking directly to affordability, the chief 
concern of health managers everywhere, and a shortcoming 
of formal health economic evaluations. This observation is 
confirmed by the case of the national guidelines for heart 
diseases illustrated by Eckard et al. (12), as the priority 
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setting group did not have any budget restriction to take into 
consideration and cost-effectiveness data was used in the 
priority setting.
Decision-making rules used to reduce uncertainty
Decision-making rules refers to the methods used to remove 
or reduce uncertainty and the need for structure in the priority 
setting process. When observing formulary committee 
members prioritise the pharmaceuticals to include in a 
formulary, I noticed quite soon that there was a connection 
between the strategies used to handle uncertainty and the use 
of cost-effectiveness data (13). A number of strategies were 
implemented in order to handle uncertainty; privileging 
one source and excluding others, delaying decisions 
(i.e. postponing decisions to a later meeting), delegating 
the decision to the prescribing physicians, calibration 
(standardise different sources), and sequential decision-
making (considering different evidence at different points 
in time) and sequential decision-making. Cost-effectiveness 
data increased in importance when the calibration strategy 
was implemented since this was data that could be included 
in meta-analyses and fitted the desired strategy to reduce 
uncertainty. Of course it is impossible to judge if it was the 
data available that influenced the preference for strategy 
to reduce uncertainty or vice versa, but there seems to be a 
interdependency at hand that is worthwhile looking closer 
into. Also, in the Eckard et al. (12) article this link between 
reducing uncertainty and use of cost-effectiveness data 
was observed. 
Transparency
When there is a demand for transparency in priority setting, 
it is suggested to increase the probability that health economic 
evaluations are used due to its relative applicability compared 
to other decision criteria (13). The most prominent health 
technology assessment agencies globally, in terms of using 
cost-effectiveness data, interestingly share the common 
feature that their decision-making process is relatively 
transparent and influenced by the theoretical framework 
“Accountability for Reasonableness” (A4R). According to 
this framework, fair and legitimate processes must fulfill 
the four conditions of publicity, relevance, revisions and 
enforcement (14). This framework is based on the ideas of 
democratic deliberation.
The publicity criterion is perceived as a guarantee for 
patterns to evolve in the priority setting. By informing 
stakeholders who are affected by the decisions, in a way which 
increases the understanding of the motives of the decision, 
the acceptance of the outcome is suggested to increase. 
Consequently, this transparency is thought to lead to the 
development of “case laws”, i.e. like cases will be treated in a 
similar way. Why cost-effectiveness data is used particularly 
in those priority setting situations where there is demand for 
transparency may be explained by the relative simplicity of 
applying cost-effectiveness compared to principles such as 
need and solidarity. Like National Institute for Health and 
Care Excellence (NICE) and TLV (the Swedish Dental and 
Pharmaceutical Benefits Board), the National Board of Health 
and Welfare is adapting transparency of priority setting in a 
similar way so fits nicely with previous experiences that cost-
effectiveness data is also used in decision-making.
Internal and external institutions
Internal and external institutions are the taken-for-granted 
assumptions that prevails in an organisation and part of the 
tacit or explicit knowledge around the values (for instance the 
relative importance of decision criteria), or the professional 
norms, underpinning the organisation or individuals 
influences the use through the rationalities and archetypes 
prevailing in the organisation. In organisations, or situations, 
when medical decision-makers do not base their decision on 
evidence, the use of cost-effectiveness data, by default, will 
be extremely limited. A fundamental pre-condition for use 
would be a preference for the rational decision-making style. 
If this is the case, the battle among the professions will center 
around what kind of information is legitimate and rational to 
use. Having studied priority setting from the inside observing 
the decision-makers in real life over time it becomes soon 
quite evident that different professions have their own 
standards and ideals they try to transfer to the organisations 
they belong to. However, in most organisations it is possible 
for multiple rationalities to co-exist and particularly so in 
priority setting groups. So in order to maximize the benefit for 
all parties involved and allowing these different standards to 
co-exist, maybe it is very rational to use different information 
in different phases of decision-making? In the case of Eckard 
et al. (12), the co-existence of multiple rationalities was 
identified as well, confirming that health economists have 
reached the point of being considered as a profession and 
thus cost-effectiveness data is legitimate to use in healthcare 
priority setting as long as there is someone there who has 
been legitimately assigned (a health economist) to translate 
and explain what it means and how it should be used. The 
constant reinforcement of including cost-effectiveness data in 
priority setting illustrated in the latter case also legitimized the 
health economist attending as a representative of a profession 
of importance.
Prevailing templates
In New Institutional Theory it is assumed that organisations 
are organised by their managers in accordance with the 
prevailing template in their field (15). This means that 
they mimic other organisations to retain legitimacy 
(isomorphism). Isomorphism results from both formal 
and informal pressure exerted on a weaker organisation by 
another stronger party which it is dependent upon, between 
two parties. The mimicking organisation aim at gaining some 
of that success, and hence legitimacy, by imitating the more 
successful organisation. In the case of the National Board of 
Health and Welfare, the agency share a common template 
for successful Health Technology Assessment (HTA) with 
other Swedish national authorities such as TLV and SBU 
(The Swedish Council of Health Technology Assessment) 
although these three national authorities have different areas 
of responsibility. All three Swedish authorities are guided by 
a national framework for priority setting which stipulates 
that the cost-effectiveness principle among other principles 
should form basis for priority setting decisions. So, in the 
Eckard et al. (12) case, there were clear instructions that cost-
effectiveness data should be part of the consideration and 
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also other prevailing templates for how to incorporate such 
data into decision-making, thus legitimating the use of cost-
effectiveness data. 
Using this framework for understanding the conditions at 
hand influencing a positive uptake of cost-effectiveness data 
in the research of Eckard et al.(12), it becomes clear that the 
key conditions for use in this priority setting context were: 1) 
clear goals and instructions that cost-effectiveness was a key 
principle for decision-making, and 2) the existence of a health 
economist who could understand and disseminate the cost-
effectiveness data to all the decision-makers in the group, 
help explain and translate the cost-effectiveness message and 
relevance into a language that made sense to those making 
the decisions.
The definition of use of cost-effectiveness data
Measuring the use of cost-effectiveness data presents a 
number of challenges for the researcher as there is no 
generally accepted definition of the use of health economic 
evaluations. So far the use has been suggested to be defined 
as dissemination, recognition, understanding and/or utilising 
(1). Based on empirical research of the British National Health 
Service (NHS) decision-making, Williams (16) suggests use 
being defined rather as a matter of requesting, accessing, 
interpreting or implementing economic evaluations. Based on 
my own previous research of the use (13), I strongly believe 
the use may also be defined accordingly to the purpose of 
the use and consequently the phase of the priority setting 
process, i.e. preparation of the decision-making, hearing of 
expert comments/evaluation of evidence, actual decision-
making and post-decision communication (rationalisation). 
Taking these different aspects of use into the consideration, 
maybe cost-effectiveness data is not rarely used any more 
even though it might not be used for rationalisation purposes. 
So the conclusion is that for cost-effectiveness data to 
be  further used in priority setting decisions, 1) we health 
economists need to be pragmatic and accept the use as 
legitimate even though the data might not be used for 
legitimising decisions to the public, and 2) for decision-
makers responsible for designing priority setting process to 
make sure the conditions discussed are fulfilled to enable the 
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